54 citations
,
September 2019 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.
November 2025 in “Eurasian journal of applied biotechnology” Combining L-cysteine, NAC, and a MET inhibitor significantly kills cervical cancer cells.
December 2025 in “International Journal of Innovative Technologies in Social Science” Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
39 citations
,
January 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.
Abemaciclib can cause skin, hair, and nail problems, leading some patients to stop using it.
1 citations
,
February 2025 in “Pediatric Dermatology” Tofacitinib helps hair regrow in some kids with severe alopecia areata, but more research is needed on long-term effects.
May 2025 in “JEADV Clinical Practice” Tofacitinib and methotrexate successfully treated a woman's severe skin, joint, and hair loss issues.
4 citations
,
January 2022 in “Dermatologic Therapy” Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.
2 citations
,
April 2022 in “Cutaneous and Ocular Toxicology” Tofacitinib may help treat hair loss in children with alopecia areata.
April 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped a person with total body hair loss grow hair again without bad side effects.
January 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Semecarpus anacardium leaf extracts may offer safe, effective cancer treatment alternatives.
September 2025 in “International Journal of Molecular Sciences” Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.
6 citations
,
December 2021 in “Journal of Cancer Research and Therapeutics” The treatment improved survival and controlled cancer spread but required managing side effects like rashes.
2 citations
,
November 2021 in “ACG Case Reports Journal” Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.
February 2011 in “Annales de dermatologie et de vénéréologie” Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
January 2024 in “International Journal of Dermatology Venereology and Leprosy Sciences” Tofacitinib may be safe and effective for treating certain skin conditions in children.
15 citations
,
November 2020 in “Pharmaceutics” Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
June 2020 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Researchers found a specific T cell receptor linked to severe drug reactions like Stevens-Johnson syndrome when patients take carbamazepine.
16 citations
,
July 2017 in “Rheumatology and Therapy” Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.
April 2024 in “Canadian Journal of Ophthalmology” A woman with advanced eye cancer went into complete remission using a combination of immunotherapy and topical treatments.
March 2005 in “Inpharma Weekly” China approved Sinovac's flu vaccine, Japan approved RiUP for female hair loss, and Nippon Kayaku's three cancer drugs.
July 2024 in “Journal of Investigative Dermatology” A new test helps find drugs to treat head and neck cancer by targeting c-Rel.
46 citations
,
February 2012 in “Oncology Reports” Sorafenib helps some advanced cancers alone or with other treatments, but not all, and research continues to improve its use.
3 citations
,
June 2023 in “Molecules/Molecules online/Molecules annual” Cepharanthine has many medicinal uses but needs improvement for better effectiveness.
October 2024 in “International Journal of Research in Dermatology” Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
19 citations
,
April 2014 in “Expert opinion on emerging drugs” New treatments for a type of skin cancer show promise but have side effects and may work better with other therapies.
January 2024 in “Dermatologic therapy” Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
78 citations
,
March 2004 in “Annals of Oncology” The treatment combining docetaxel, cisplatin, and 5-FU is feasible and effective for advanced head and neck cancer.
11 citations
,
January 2020 in “Dermatologica Sinica” Tofacitinib helps regrow hair in severe alopecia patients, but more research is needed.